IPI-504 blocks a protein that is in cancer cells and is also in normal cells. This protein is
called Heat Shock Protein-90 (Hsp90). Hsp90 helps protect certain other proteins from being
destroyed by cells. These proteins can mutate to give off signals that allow cancer cells to
keep growing. By blocking the function of Hsp90, we hope that the cancer cell will block the
mutated protein and cause the cancer cells to die. This drug have been used in other research
studies and in the laboratory and information from those other research studies suggests that
thsi drug may help to treat lung cancer with ALK mutations. In this research study, we are
looking to see what effects IPI-504 has in patients with lung cancer who have an ALK
mutation.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Dana-Farber Cancer Institute Infinity Pharmaceuticals, Inc.